PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
176.45 - 178.59
86.62 - 184.48
124.91M / 173.95M (Avg.)
50.81 | 3.50
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
15.31%
Revenue growth similar to AVGO's 14.59%. Walter Schloss would see if both companies share industry tailwinds.
17.74%
Gross profit growth above 1.5x AVGO's 11.76%. David Dodd would confirm if the company's business model is superior in terms of production costs or pricing.
80.64%
EBIT growth above 1.5x AVGO's 18.64%. David Dodd would confirm if core operations or niche positioning yield superior profitability.
80.64%
Operating income growth above 1.5x AVGO's 18.64%. David Dodd would confirm if consistent cost or pricing advantages drive this outperformance.
75.63%
Net income growth above 1.5x AVGO's 25.66%. David Dodd would check if a unique moat or cost structure secures superior bottom-line gains.
77.08%
EPS growth above 1.5x AVGO's 23.91%. David Dodd would review if superior product economics or effective buybacks drive the outperformance.
72.92%
Diluted EPS growth above 1.5x AVGO's 24.44%. David Dodd would see if there's a robust moat protecting these shareholder gains.
0.54%
Share count expansion well above AVGO's 0.81%. Michael Burry would question if management is raising capital unnecessarily or is over-incentivizing employees with stock.
0.92%
Diluted share count expanding well above AVGO's 0.40%. Michael Burry would fear significant dilution to existing owners' stakes.
No Data
No Data available this quarter, please select a different quarter.
-9.66%
Both companies show negative OCF growth. Martin Whitman would analyze broader economic or industry conditions limiting cash flow.
-1.54%
Both companies show negative FCF growth. Martin Whitman would consider an industry-wide capital spending surge or margin compression.
106.83%
10Y revenue/share CAGR above 1.5x AVGO's 26.59%. David Dodd would confirm if management’s strategic vision consistently outperforms the competitor.
-3.75%
Negative 5Y CAGR while AVGO stands at 26.59%. Joel Greenblatt would push for a turnaround plan or reevaluation of the company’s product line.
18.09%
3Y revenue/share CAGR 1.25-1.5x AVGO's 12.84%. Bruce Berkowitz might see better product or regional expansions than the competitor.
46.98%
10Y OCF/share CAGR under 50% of AVGO's 97.03%. Michael Burry would worry about a persistent underperformance in cash creation.
-57.43%
Negative 5Y OCF/share CAGR while AVGO is at 97.03%. Joel Greenblatt would question the firm’s operational model or cost structure.
13.76%
Positive 3Y OCF/share CAGR while AVGO is negative. John Neff might see a big short-term edge in operational efficiency.
417.74%
Net income/share CAGR above 1.5x AVGO's 178.48% over 10 years. David Dodd would confirm if brand, IP, or scale secure this persistent advantage.
-20.89%
Negative 5Y net income/share CAGR while AVGO is 178.48%. Joel Greenblatt would see fundamental missteps limiting profitability vs. the competitor.
72.16%
3Y net income/share CAGR above 1.5x AVGO's 11.26%. David Dodd would confirm the company’s short-term strategies outmatch the competitor significantly.
297.00%
Equity/share CAGR of 297.00% while AVGO is zero. Bruce Berkowitz might see a slight advantage that can compound significantly over 10 years.
69.96%
Equity/share CAGR of 69.96% while AVGO is zero. Bruce Berkowitz might see a minor advantage that could compound if the firm maintains positive net worth growth.
72.61%
3Y equity/share CAGR at 50-75% of AVGO's 97.08%. Martin Whitman sees a short-term lag in net worth creation vs. the competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-0.08%
Firm’s AR is declining while AVGO shows 34.69%. Joel Greenblatt sees stronger working capital efficiency if sales hold up.
10.80%
Inventory shrinking or stable vs. AVGO's 24.02%. David Dodd confirms the company’s supply-chain is more efficient if sales are unaffected.
3.11%
Asset growth at 50-75% of AVGO's 5.26%. Martin Whitman questions if the firm is lagging expansions or if the competitor invests more aggressively.
5.47%
BV/share growth above 1.5x AVGO's 3.56%. David Dodd confirms if consistent profit retention or fewer write-downs yield faster equity creation.
-3.01%
We’re deleveraging while AVGO stands at 0.00%. Joel Greenblatt considers if we gain a balance-sheet advantage for potential downturns.
1.06%
R&D dropping or stable vs. AVGO's 6.32%. David Dodd sees near-term margin benefits if the product pipeline is already strong.
-16.38%
We cut SG&A while AVGO invests at 9.62%. Joel Greenblatt sees a short-term margin benefit but wonders if the competitor invests for future gains.